What Happened?
Cambridge, MA-based Werewolf-Therapeutics Appointed Dan Hicklin as Founder President and Chief Executive Officer
Date of management change: December 15, 2018
Cambridge, MA-based Werewolf-Therapeutics Appointed Dan Hicklin as Founder President and Chief Executive Officer
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Dan Hicklin is Founder President and Chief Executive Officer at Werewolf Therapeutics. Previously, Dan held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Dillard Lauren, Franca Colleen, Matuska Vilay, Encarnacao Diane, Fischer Rebecca, Dirkes Denice, Keirns Morag, Roeder Jennifer, Toliver Ray, Asebrook Mike, van Niekerk Amber
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.